
Joana Bicker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1197062/publications.pdf Version: 2024-02-01



IOANA RICKED

#	Article	IF	CITATIONS
1	Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 409-432.	4.3	222
2	Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples—A review. Analytica Chimica Acta, 2013, 768, 12-34.	5.4	149
3	ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. Pharmacological Research, 2019, 144, 357-376.	7.1	49
4	Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics. British Journal of Pharmacology, 2020, 177, 2215-2239.	5.4	46
5	A new PAMPA model using an in-house brain lipid extract for screening the blood–brain barrier permeability of drug candidates. International Journal of Pharmaceutics, 2016, 501, 102-111.	5.2	41
6	Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113109.	2.8	41
7	Nose-to-brain delivery of levetiracetam after intranasal administration to mice. International Journal of Pharmaceutics, 2019, 564, 329-339.	5.2	40
8	QbD-driven development of intranasal lipid nanoparticles for depression treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 106-120.	4.3	29
9	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	10.9	26
10	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. Analytica Chimica Acta, 2019, 1076, 18-31.	5.4	24
11	Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discovery Today, 2019, 24, 1911-1923.	6.4	23
12	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol- <i>O</i> -Methyltransferase Inhibitors. Drug Metabolism and Disposition, 2017, 45, 1282-1291.	3.3	19
13	Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sciences, 2021, 275, 119342.	4.3	18
14	Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. Bioanalysis, 2018, 10, 541-557.	1.5	17
15	Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders. Current Pharmaceutical Design, 2020, 26, 594-619.	1.9	17
16	A chiral HPLCâ€UV method for the quantification of dibenz[b,f]azepineâ€5â€carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolites. Journal of Separation Science, 2011, 34, 1391-1401.	2.5	15
17	A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. International Journal of Pharmaceutics, 2021, 593, 120161.	5.2	15
18	Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration. Pharmaceutical Research, 2020, 37, 74.	3.5	13

JOANA BICKER

#	Article	IF	CITATIONS
19	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. Life Sciences, 2020, 240, 117093.	4.3	12
20	Cystic fibrosis: Physiopathology and the latest pharmacological treatments. Pharmacological Research, 2020, 162, 105267.	7.1	12
21	Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression. Pharmaceutics, 2021, 13, 1975.	4.5	12
22	Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1162, 122491.	2.3	10
23	Screening of pharmacokinetic properties of fifty dihydropyrimidin(thi)one derivatives using a combo of in vitro and in silico assays. European Journal of Pharmaceutical Sciences, 2017, 109, 334-346.	4.0	9
24	In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. European Journal of Pharmaceutical Sciences, 2018, 117, 35-40.	4.0	9
25	Is intranasal administration an opportunity for direct brain delivery of lacosamide?. European Journal of Pharmaceutical Sciences, 2021, 157, 105632.	4.0	9
26	Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. Frontiers in Pharmacology, 2021, 12, 751321.	3.5	8
27	HPLC method for the determination of antiepileptic drugs in human saliva and its application in therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113961.	2.8	7
28	Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective. Current Drug Metabolism, 2018, 19, 1021-1041.	1.2	7
29	Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders. Pharmacological Research, 2020, 162, 105226.	7.1	3
30	Pharmacokinetic Monitoring of Levetiracetam in Portuguese Refractory Epileptic Patients: Effect of Gender, Weight and Concomitant Therapy. Pharmaceutics, 2020, 12, 943.	4.5	3
31	Novel Routes to Accessing the Brain: Intranasal Administration. , 2021, , 39-72.		0